MED-TIMA Kft
Welcome,         Profile    Billing    Logout  
 1 Trial 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang
EMERALD, NCT05001737 / 2021-001577-24: Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Recruiting
3
41
Europe, Canada, Japan, US, RoW
Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO)
Swedish Orphan Biovitrum
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
09/24
09/25
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Recruiting
3
320
Europe, Canada, US, RoW
DZD9008, Pemetrexed+carboplatin
Dizal Pharmaceuticals
Non-small Cell Lung Cancer
02/26
10/27
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL

Completed
2
171
US, RoW
AZD4205
Dizal Pharmaceuticals
Relapsed or Refractory Peripheral T Cell Lymphoma
10/23
02/24
NCT06175351: Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Recruiting
1/2
80
RoW
9MW1911, Placebo
Mabwell (Shanghai) Bioscience Co., Ltd.
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
09/25
09/25
NCT06239623: ERK Inhibitor JSI-1187 in Advanced Solid Tumors

Recruiting
1
60
RoW
JSI-1187
JS InnoPharm, LLC
Solid Tumor, NSCLC, Melanoma
09/24
12/24
NCT05508100: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Completed
1
38
RoW
IO-108, IO-108 + pembrolizumab, IO-108 + Keytruda®, IO-108 + tislelizumab
Immune-Onc Therapeutics
Advanced Solid Tumor
04/24
04/24
NCT05895565: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects

Recruiting
1
28
RoW
PMG1015, PMG1015 placebo
Pulmongene Ltd.
IPF
12/24
05/25
Tanczer
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26

Download Options